IDH1 and IDH2 mutations drive cancer through excessive D-2-hydroxyglutarate (D-2HG) production, disrupting metabolism and epigenetic regulation, and serve as biomarkers for detection and targeted therapy in specific cancers [42]. This evidence concerns the gene IDH2 and cancer.